Performance of Risk Stratification Tools for Cephalosporin Allergy Testing

Ami P Belmont; Maren Valente; Aster Workineh; Samantha Novotny; Jason Kwah; Chang Su; Katelyn H. Wong; Elizabeth J. Phillips; Cosby A. Stone

doi:10.1001/jamanetworkopen.2026.34079

September 16, 2026JAMA Network OpenOpen Access

Performance of Risk Stratification Tools for Cephalosporin Allergy Testing

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate and compare the diagnostic validity of the CEPH-FAST, Urticaria 1-1-1, and Vanderbilt criteria for risk stratification in patients with reported cephalosporin allergy.
Conducted a cross-sectional study evaluating patients presenting with reported cephalosporin allergy.
Assessed the predictive performance and validity of three clinical stratification tools: CEPH-FAST, Urticaria 1-1-1, and Vanderbilt criteria.
Demonstrated the clinical performance and validity of CEPH-FAST, Urticaria 1-1-1, and Vanderbilt criteria for stratifying cephalosporin allergy risk.
Established comparative risk-assessment utility among the three evaluated screening protocols for allergy testing.

Abstract

This cross-sectional study reports the validity of CEPH-FAST, Urticaria 1-1-1, and Vanderbilt criteria for use in patients with cephalosporin allergy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Belmont et al. (2026) studied this question.

synapsesocial.com/papers/6aabb8045f706d05830e779f https://doi.org/10.1001/jamanetworkopen.2026.34079

View Full Paper

Ask AI

Bookmark

Share

Performance of Risk Stratification Tools for Cephalosporin Allergy Testing

Key Points

Abstract

Discussion

Cite This Study

Performance of Risk Stratification Tools for Cephalosporin Allergy Testing

Key Points

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from JAMA Network Open

Keep reading

More related papers

More from JAMA Network Open